ÂÜÀòÂÒÂ×

Dr. Philippe MONTEYNE MD, Ph.D. is a Partner at Fund+ in Belgium. Fund+ is an open-ended venture fund for long-term equity investments in innovative life sciences companies with a focus on Belgium. The fund wants to create sustainable shareholders’ value, contribute to the development of a leadership position of the Life Sciences sector and generate a tangible, beneficial societal impact. Dr. Monteyne has held senior positions in SmithKline Beecham, GSK, and Sanofi. He served as the Head of Global Vaccine Development at GSK for several years, and then served as Senior VP-Head of Development and CMO at GSK Rare Diseases from 2010 to 2012. More recently, he served as Vice President of R&D France at Sanofi until early 2015. During that period, he was also Board Member of SARD (Sanofi Aventis R&D), of the LEEM (Pharmaceutical association in France "Les Entreprises du Médicament"), of the Technological Research Institute (IRT) Bioaster in Lyon, and of the « Fondation Plan Alzheimer France ». He is a Director of different Biotech companies, in Belgium, France, and Spain. Dr. Monteyne was also visiting Professor of Neurology at the UCL (Université Catholique de Louvain), Brussels. He holds an M.D. degree in 1989 and Ph.D. in Viral Immunology in 1995, both at the UCL, is a fully trained Neurologist, and has also been trained in Neuro-Immunology at Pasteur Institute in Paris.